Document is current
Any future updates will be listed below
-
Authors
Hernandez, Gloria E. https://orcid.org/0000-0003-2882-811X
Ma, Feiyang https://orcid.org/0000-0002-6260-0787
Martinez, Guadalupe
Firozabadi, Nadia B.
Salvador, Jocelynda
Juang, Lih Jiin
Leung, Jerry https://orcid.org/0000-0002-8714-8440
Zhao, Peng https://orcid.org/0000-0002-6610-6217
López, Diego A. https://orcid.org/0000-0003-3989-3785
Ardehali, Reza https://orcid.org/0000-0003-1318-4016
Beaudin, Anna E.
Kastrup, Christian J.
Pellegrini, Matteo https://orcid.org/0000-0001-9355-9564
Flick, Matthew J.
Iruela-Arispe, M. Luisa https://orcid.org/0000-0002-3050-4168
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute (GT11560, GT11560)
National Institute of Health
Canadian National Institute of Health
DH | National Institute for Health Research (R35HL140014)
- License Information
-
More Information
Article History
Received: 13 June 2021
Accepted: 17 November 2021
First Online: 12 January 2022
Competing interests
: C.J.K. is a director and shareholder of NanoVation Therapeutics Inc., which is commercializing RNA-based therapies. C.J.K., L.J.J. and J.L. have filed intellectual property on RNA-based therapies, with the intention of commercializing these inventions. All other authors declare no competing interests.
